Table 5.
Multinomial logistic regression model: Prediction of Response (second-line)
| Factor | p = | OR | 95% CI |
|---|---|---|---|
| Age > 65 years | 0.392 | 0.35 | 0.03-3.9 |
| Age < 35 years | 0.363 | 0.3 | 0.02-4 |
| Stage 4 at diagnosis | 0.839 | 1.11 | 0.4-3.14 |
| Grading (1,2 versus 3) | 0.268 | 0.37 | 0.06-2.15 |
| Histologic type (ductal versus lobular) | 0.19 | 0.17 | 0.01-2.41 |
| Positive hormone receptor status | 0.534 | 0.63 | 0.15-2.68 |
| Time to recurrence < 12 months | 0.332 | 0.43 | 0.08-2.36 |
| Visceral metastases | 0.147 | 3.96 | 0.62-25-35 |
| Number of metastatic sites (1 versus 2) | 0.318 | 0.36 | 0.05-2.64 |
| Number of metastatic sites (2 versus > 2) | 0.792 | 0.82 | 0.18-3.63 |
| Trastuzumab from first-line palliative treatment | 0.886 | 1.15 | 0.18-7.53 |
| Response to fist-line trastuzumab-based therapy | 0.201 | 2.58 | 0.6-11-08 |
| New metastatic sites at progression upon first-line trastuzumab-based therapy | 0.953 | 1.04 | 0.28-3.84 |